Abstract: A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.

Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Abstract: A method of purifying a high specific activity Sn-117m composition is provided that includes extracting an iodide complex of Sn-117m with an organic solvent from an acidic aqueous cadmium solution comprising a dissolved irradiated cadmium target, an acid, and a source of iodide. The organic solvent layer comprising the iodide complex of Sn-117m is substantially reduced in cadmium content. The Sn-117m may be back extracted into an aqueous solution.

Abstract: Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.

Abstract: A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.

Abstract: Amine modified dextran is labeled with mannose molecules as well as tin-117m. This tin-117m labeled mannose modified dextran is useful in treating maladies that express CD206, in particular rheumatoid arthritis, as well as the cancer typically located in the lymph nodes. This provides a systemic treatment for such maladies. The tin-117m will destroy cells to which it is bonded and also can be imaged. Further, due to the nature of the radiation from the tin-117m, it does not do significant damage to nearby healthy cells.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.

Abstract: A system for the recovery and management of atmospheric gas is disclosed, such as for use as a vehicle propellant in a vehicle propulsion system. The system can include a compressor configured to compress atmospheric gas and first and second storage tanks configured to store liquefied atmospheric gas from the compressor. The second storage tank can have a heater operable to heat liquefied atmospheric gas therein to convert it to a high pressure gas. The second storage tank includes an outlet duct fluidly coupled to the first storage tank for supplying high pressure gas to the first storage tank.

Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression.

Abstract: An ophthalmic radiation device using a polymeric radiation-source implemented as either a polymer molecularly bonded with a radioisotope or a polymeric encasement of a radioisotope.

Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Abstract: A method of purifying a high specific activity Sn-117m composition is provided that includes extracting an iodide complex of Sn-117m with an organic solvent from an acidic aqueous cadmium solution comprising a dissolved irradiated cadmium target, an acid, and a source of iodide. The organic solvent layer comprising the iodide complex of Sn-117m is substantially reduced in cadmium content. The Sn-117m may be back extracted into an aqueous solution.

Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Abstract: Methods for generating an Ac-225 radioconjugate comprising a monoclonal antibody (mAb) (IgG) is disclosed. The Ac-225 radioimmunoconjugate is an [Ac-225]-p-SCN-Bn-DOT AIHuM195 radioimmunoconjugate.

Abstract: Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analogue is also disclosed, as well as novel methods to produce the tin labeled analogues and antagonists.

Abstract: Tin-117m somatoostatin analogs or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analog is also disclosed, as well as novel methods to produce the tin labeled analogs and antagonists.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.

Abstract: An ophthalmic radiation device using a polymeric radiation-source implemented as either a polymer molecularly bonded with a radioisotope or a polymeric encasement of a radioisotope.

Abstract: A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.